COH34 is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase (PARG) with an IC50 value of 0.37 nM. It binds to the catalytic domain of PARG with Kd of 0.547 μM thereby prolonging PARylation at DNA lesions and trapping DNA repair factors and can be used in research of cancer therapies.

2-NP (2-(1,8-Naphthyridin-2-yl)phenol) is a selective enhancer of STAT1 transcription. It enhances the antiproliferative effects of IFN-γ on human breast cancer and fibrosarcoma cells.

MeAIB (α-(Methylamino)isobutyric acid) is a specific substrate for amino acid transport system A, especially System A (ATA1). It also inhibits SNAT2, which reduces intracellular levels of essential amino acids and impairs cell proliferation in porcine enterocytes by disrupting the mTOR signalling pathway.

MeAIB (α-(Methylamino)isobutyric acid) is a specific substrate for amino acid transport system A, especially System A (ATA1). It also inhibits SNAT2, which reduces intracellular levels of essential amino acids and impairs cell proliferation in porcine enterocytes by disrupting the mTOR signalling pathway.

FDW028 is a highly potent and selective inhibitor of FUT8. FDW028 demonstrates strong anti-tumor effects by promoting defucosylation and inducing lysosomal degradation of B7-H3 via the chaperone-mediated autophagy (CMA) pathway. Additionally, FDW028 suppresses the AKT/mTOR signaling pathway. FDW028 exhibits potent anti-Metastatic colorectal cancer (mCRC) activities.

FDW028 is a highly potent and selective inhibitor of FUT8. FDW028 demonstrates strong anti-tumor effects by promoting defucosylation and inducing lysosomal degradation of B7-H3 via the chaperone-mediated autophagy (CMA) pathway. Additionally, FDW028 suppresses the AKT/mTOR signaling pathway. FDW028 exhibits potent anti-Metastatic colorectal cancer (mCRC) activities.

FDW028 is a highly potent and selective inhibitor of FUT8. FDW028 demonstrates strong anti-tumor effects by promoting defucosylation and inducing lysosomal degradation of B7-H3 via the chaperone-mediated autophagy (CMA) pathway. Additionally, FDW028 suppresses the AKT/mTOR signaling pathway. FDW028 exhibits potent anti-Metastatic colorectal cancer (mCRC) activities.

VVD-130037(BAY-3605349) is an orally available covalent small molecule activator of Kelch-like ECH associated protein 1 (KEAP1), which provide enhanced cellular degradation of nuclear factor-erythroid 2 p45-related factor 2 (NRF2) resulting in significant inhibition of tumor growth in advanced solid tumors.

VVD-130037(BAY-3605349) is an orally available covalent small molecule activator of Kelch-like ECH associated protein 1 (KEAP1), which provide enhanced cellular degradation of nuclear factor-erythroid 2 p45-related factor 2 (NRF2) resulting in significant inhibition of tumor growth in advanced solid tumors.

FDW028 is a highly potent and selective inhibitor of FUT8. FDW028 demonstrates strong anti-tumor effects by promoting defucosylation and inducing lysosomal degradation of B7-H3 via the chaperone-mediated autophagy (CMA) pathway. Additionally, FDW028 suppresses the AKT/mTOR signaling pathway. FDW028 exhibits potent anti-Metastatic colorectal cancer (mCRC) activities.